Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216836855> ?p ?o ?g. }
- W3216836855 endingPage "259" @default.
- W3216836855 startingPage "245" @default.
- W3216836855 abstract "Oncolytic virotherapy has currently emerged as a powerful therapeutic approach in cancer treatment. Although the history of using viruses goes back to the early 20th century, the approval of talimogene laherparepvec (T-VEC) in 2015 increased interest in oncolytic viruses (OVs). OVs are multifaceted biotherapeutic agents because they replicate in and kill tumor cells and augment immune responses by releasing immunostimulatory molecules from lysed cells. Despite promising results, some limitations hinder the efficacy of oncolytic virotherapy. The delivery challenges and the upregulation of checkpoints following oncolytic virotherapy also mediate resistance to OVs by diminishing immune responses. Furthermore, the localization of receptors of viruses in the tight junctions, interferon responses, and the aberrant expression of genes involved in the cell cycle of the virus, including their infection and replication, reduce the efficacy of OVs. In this review, we present different mechanisms of resistance to OVs and strategies to overcome them.Lay abstract Using viruses in the treatment of cancer goes back to the early 20th century. One of the promising fields in cancer virotherapy is viruses’ ability to preferentially lysis tumor cells, either naturally or genetically engineered cells; these viruses are termed ‘oncolytic viruses.’ As with other therapeutic strategies, resistance to the oncolytic viruses is the main challenge in their application in clinical trials. This review summarizes the mechanisms of resistance to oncolytic viruses and the strategies that have been used to overcome these challenges." @default.
- W3216836855 created "2021-12-06" @default.
- W3216836855 creator A5004687402 @default.
- W3216836855 creator A5012774851 @default.
- W3216836855 creator A5035679742 @default.
- W3216836855 creator A5045025022 @default.
- W3216836855 creator A5064091979 @default.
- W3216836855 creator A5068996543 @default.
- W3216836855 creator A5071661232 @default.
- W3216836855 date "2022-01-01" @default.
- W3216836855 modified "2023-10-09" @default.
- W3216836855 title "Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses" @default.
- W3216836855 cites W1269896974 @default.
- W3216836855 cites W1819766659 @default.
- W3216836855 cites W1927596245 @default.
- W3216836855 cites W1971765707 @default.
- W3216836855 cites W1976177182 @default.
- W3216836855 cites W1978834861 @default.
- W3216836855 cites W1987904386 @default.
- W3216836855 cites W1988658787 @default.
- W3216836855 cites W1992512657 @default.
- W3216836855 cites W1992988367 @default.
- W3216836855 cites W1995243829 @default.
- W3216836855 cites W1997221411 @default.
- W3216836855 cites W1997634655 @default.
- W3216836855 cites W1998506044 @default.
- W3216836855 cites W2001371234 @default.
- W3216836855 cites W2003665515 @default.
- W3216836855 cites W2010328268 @default.
- W3216836855 cites W2011167174 @default.
- W3216836855 cites W2015873632 @default.
- W3216836855 cites W2018127420 @default.
- W3216836855 cites W2025064244 @default.
- W3216836855 cites W2027719557 @default.
- W3216836855 cites W2028182670 @default.
- W3216836855 cites W2031946360 @default.
- W3216836855 cites W2034901529 @default.
- W3216836855 cites W2035933478 @default.
- W3216836855 cites W2039084800 @default.
- W3216836855 cites W2044565334 @default.
- W3216836855 cites W2045920958 @default.
- W3216836855 cites W2048727901 @default.
- W3216836855 cites W2049352377 @default.
- W3216836855 cites W2054540190 @default.
- W3216836855 cites W2059995794 @default.
- W3216836855 cites W2060359878 @default.
- W3216836855 cites W2061338310 @default.
- W3216836855 cites W2061410746 @default.
- W3216836855 cites W2073134590 @default.
- W3216836855 cites W2075631864 @default.
- W3216836855 cites W2076761426 @default.
- W3216836855 cites W2080428594 @default.
- W3216836855 cites W2091377832 @default.
- W3216836855 cites W2092037848 @default.
- W3216836855 cites W2092055002 @default.
- W3216836855 cites W2095394300 @default.
- W3216836855 cites W2100342970 @default.
- W3216836855 cites W2103565638 @default.
- W3216836855 cites W2105848229 @default.
- W3216836855 cites W2109274792 @default.
- W3216836855 cites W2113188427 @default.
- W3216836855 cites W2114363080 @default.
- W3216836855 cites W2116345938 @default.
- W3216836855 cites W2117160925 @default.
- W3216836855 cites W2123291849 @default.
- W3216836855 cites W2123363275 @default.
- W3216836855 cites W2129244956 @default.
- W3216836855 cites W2132819533 @default.
- W3216836855 cites W2134119060 @default.
- W3216836855 cites W2136443494 @default.
- W3216836855 cites W2140521865 @default.
- W3216836855 cites W2141753696 @default.
- W3216836855 cites W2155304024 @default.
- W3216836855 cites W2177826333 @default.
- W3216836855 cites W2202852041 @default.
- W3216836855 cites W2278652105 @default.
- W3216836855 cites W2339396473 @default.
- W3216836855 cites W2399245969 @default.
- W3216836855 cites W2406631797 @default.
- W3216836855 cites W2503534199 @default.
- W3216836855 cites W2508324452 @default.
- W3216836855 cites W2508710837 @default.
- W3216836855 cites W2509143635 @default.
- W3216836855 cites W2539571618 @default.
- W3216836855 cites W2552993899 @default.
- W3216836855 cites W2561037714 @default.
- W3216836855 cites W2581230996 @default.
- W3216836855 cites W2586637063 @default.
- W3216836855 cites W2590596176 @default.
- W3216836855 cites W2595403257 @default.
- W3216836855 cites W2596479132 @default.
- W3216836855 cites W2620207365 @default.
- W3216836855 cites W2735963593 @default.
- W3216836855 cites W2736888159 @default.
- W3216836855 cites W2745766138 @default.
- W3216836855 cites W2751454205 @default.
- W3216836855 cites W2771259184 @default.
- W3216836855 cites W2790846508 @default.